 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- V180 / Merck (MSD), live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
Phase 1 trial to model primary, secondary, and tertiary dengue infection using a monovalent vaccine (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1987;
P1
We are conducting a partially blinded phase I vaccine trial (NCT05691530) to examine how natural immunity influences the signs and symptoms, viremia, and immune responses to a dengue vaccine...Ongoing work will evaluate neutrophil and T cell responses, and germinal center changes using sequential fine needle lymph node aspirates. This study will elucidate the immunological factors driving the induction of cross-serotypic protective immunity, inform correlates of protection, and highlight potential therapeutic targets.
- | TV003 / Medigen Biotech, National Institute of Allergy and Infectious Diseases, live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
Trial completion: Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge (clinicaltrials.gov) - Nov 27, 2019
P1, N=64, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This study will elucidate the immunological factors driving the induction of cross-serotypic protective immunity, inform correlates of protection, and highlight potential therapeutic targets. Active, not recruiting --> Completed
- | TV003 / Medigen Biotech, National Institute of Allergy and Infectious Diseases, live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge (clinicaltrials.gov) - Feb 27, 2019
P1, N=64, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | TV005 / National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date, Trial primary completion date: Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3?30 (clinicaltrials.gov) - Feb 8, 2018
P1, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Nov 2017 | Trial completion date: Dec 2017 --> Nov 2017
- | TV003 / Medigen Biotech, National Institute of Allergy and Infectious Diseases, live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge (clinicaltrials.gov) - Jan 30, 2018
P1, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
Trial completion, Trial primary completion date: Evaluation of the Safety and Immunogenicity of rDEN3?30, a Live Attenuated Monovalent Dengue Virus Vaccine (clinicaltrials.gov) - Nov 30, 2016
P1, N=14, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Nov 2017 | Trial completion date: Dec 2017 --> Nov 2017 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016
- TV005 / National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3?30 (clinicaltrials.gov) - Sep 17, 2016
P1, N=48, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- TV005 / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3?30 (clinicaltrials.gov) - Aug 18, 2016
P1, N=48, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- live attenuated monovalent dengue virus vaccine (rDEN3?30) / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluation of the Safety and Immunogenicity of rDEN3?30, a Live Attenuated Monovalent Dengue Virus Vaccine (clinicaltrials.gov) - Feb 18, 2016
P1, N=14, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)